Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 30, 2006

Nycomed Will Pay Durect up to $202M in Posidur Development Agreement

  • Durect and Nycomed will jointly develop Durect’s Posidur™ post-operative pain relief depot. Posidur is currently in Phase II trials. Under the terms of the agreement, Nycomed will pay Durect an upfront license fee of $14 million, with additional milestone payments of up to $188 million upon achievement of defined development, regulatory, and sales milestones.

    The two parties will jointly direct and equally fund a development program for Posidur intended to secure regulatory approval in both the U.S. and the E.U.

    Nycomed will have exclusive commercialization rights in Europe and other select countries, and Durect will retain full ownership of Posidur in the U.S., Canada, Asia, and other countries. Durect will manufacture and supply the product to Nycomed for sale. Nycomed will pay Durect blended royalties on sales in the defined territory of 15–40% depending on annual sales.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »